


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Riverview Health 2. 395 Westfield Rd. P.O. Box 220 Noblesville, IN 46060		In accordance with letter dated September 15, 2022, 3. License No.: 13-16286-01 is amended in its entirety to read as follows:	4. Expiration Date: November 30, 2035 5. Docket No.: 030-10729 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 31.11	7. Chemical and/or physical form A. Any B. Any C. Any D. Prepackaged Kits	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 200 millicuries total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For use in in-vitro studies.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-16286-01

Docket or Reference No.:
030-10729

Amendment No. 43

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 395 Westfield Rd., Noblesville, Indiana, 46060.
11. The Radiation Safety Officer (RSO) for this license is Phillip R. Partlan, R.T.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Caryn Cockerill Anderson, M.D.

10 CFR 35.100,10 CFR 35.200

Anwar T. Ashraf, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Edward R. Bartley, M.D.

10 CFR 35.100,10 CFR 35.200

Richard L. Becker, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Eric E. Beltz, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Margaret Brengle, M.D.

10 CFR 35.100,10 CFR 35.200

Matthew Brown, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Michael S. Conley, M.D.

10 CFR 35.100,10 CFR 35.200

Anthony J. Cossell, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200

Ryan Matthew Dhaemers, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-16286-01

Docket or Reference No.:

030-10729

Amendment No. 43

Authorized User (M.D., D.O., etc.)Material and Use

Joshua D. Dowell, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Jack M. Drew, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Laura Dugan, M.D.

10 CFR 35.100, 10 CFR 35.200

Martha Dwenger, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Eric D. Elliott, M.D.

10 CFR 35.100, 10 CFR 35.200

Janalyn P. Ferguson, M.D.

10 CFR 35.100, 10 CFR 35.200

William C. Fischer, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Vincent L. Flanders, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Steven A. Fritsch, M.D.

10 CFR 35.100, 10 CFR 35.200

David R. Gulliver, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Thomas Hagman, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Richard L. Hallett, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Warren Kent Hansen, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Carolyn R. Herman, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Kelly K. Horst, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Jaimie M. Howell, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Anthony C. Illing, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Matthew M. Jones, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-16286-01

Docket or Reference No.:
030-10729

Amendment No. 43

Authorized User (M.D., D.O., etc.)Material and Use

Theodore P. Labus, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Carlo Roberto Lazzaro, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Charles A. Lerner, M.D.

10 CFR 35.100, 10 CFR 35.200

Matthew Locker, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

John Mark Michael, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jane S. Mitchell, M.D.

10 CFR 35.100, 10 CFR 35.200

John A. Morton, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jack J. Moss, M.D.

10 CFR 35.100, 10 CFR 35.200

Charles C. Mulry, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Akash M. Patel, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Anuj A. Patel, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

J. Michael Phelps, Jr., M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Frank J. Pistoia, M.D.

10 CFR 35.100, 10 CFR 35.200

Ryan N. Sauer, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Cristina N. Shinaver, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Michael S. Skulski, M.D.

10 CFR 35.100, 10 CFR 35.200

Larry L. Stover, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Marc P. Underhill, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Lori J. Wells, M.D.

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-16286-01

Docket or Reference No.:
030-10729

Amendment No. 43


Authorized User (M.D., D.O., etc.)

Brian J. Wiegel, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated July 6, 2020 (ML20202A661)
 - B. Letter dated October 27, 2020 (ML20303A218)
 - C. Letter dated September 15, 2022 (ML22262A191)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 10, 2022By: _____
Magdalena R. Gryglak
Region 3